Amgen succumbs to Singapore's charms as new production site
This article was originally published in Scrip
Executive Summary
While data released at the end of last year showed a fall in corporate R&D spending in Singapore's biomedical sciences sector, the Asian island state appears to be having fewer problems attracting new capital inflow in its traditional stronghold of pharma manufacturing.